Company news
Connect Biopharma Holdings Limited (NASDAQ:CNTB) news
Connect Biopharma Holdings Limited news releases on 6ix. Latest, Sep 30, 2026: Connect Biopharma Announces Positive Preliminary Topline Data from its Global…
Press releases & updates
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
September 29, 2026
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
September 30, 2026
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
September 15, 2026
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
June 17, 2026
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 12, 2026
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
April 22, 2026
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
March 30, 2026
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
March 29, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 29, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
March 3, 2026
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
January 11, 2026
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
November 24, 2025
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
November 14, 2025
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
November 11, 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3
October 30, 2025
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
September 29, 2025
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
September 3, 2025
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
September 2, 2025
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
August 27, 2025
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
August 14, 2025
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
July 21, 2025
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
July 20, 2025
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
July 18, 2025
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 16, 2025
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
July 9, 2025
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
June 13, 2025
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
June 2, 2025
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
May 28, 2025
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
May 20, 2025
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
May 14, 2025
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
May 12, 2025
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
April 23, 2025
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
March 31, 2025
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
March 30, 2025
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
March 30, 2025
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 27, 2025
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
September 4, 2024
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
June 11, 2024
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
May 21, 2024
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
May 6, 2024
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 15, 2024
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
February 11, 2024